What Is Taletrectinib (Ibtrozi)? FDA Approval, Licensing in Türkiye, and Reimbursement Status
| Active ingredient | Taletrectinib (taletrectinib succinate) |
| Brand name | Ibtrozi |
| Class | Next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) — oral |
| Category | Targeted therapy (oncology agent) |
| Route of administration | By mouth (oral), capsules — on an empty stomach (no food for 2 hours before and 2 hours after taking it) |
| Dosing frequency / dose | 600 mg once daily (approved dose) |
| Approved cancer indication | Locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC) |
| Approved treatment line | Both 1st-line (TKI-naïve) and patients progressing on a previous ROS1 TKI are eligible |
| FDA-approved | Yes — 11 June 2025 |
| Common concomitant drugs | Single agent (monotherapy) |
| Manufacturer | AnHeart Therapeutics / Nuvation Bio |
| Turkish Ministry of Health license | NONE |
| SGK reimbursement | NONE |
| Access in Türkiye | Only through Off-Label Approval + procurement from abroad (paid by the patient) |
| Half-life | Approximately 30–40 hours (allowing once-daily dosing) |
Taletrectinib (Ibtrozi) is an oral treatment developed for a rare but treatable lung cancer subtype: ROS1 fusion-positive non-small cell lung cancer (NSCLC). It is a next-generation targeted therapy. ROS1+ lung cancer accounts for approximately 1–2% of all NSCLC; it is often seen in younger patients who have never smoked.
This monograph covers how the drug works, which patients and treatment lines it is used in (we make this particularly explicit), TRUST-I and TRUST-II data, differences from other ROS1 drugs, its safety profile, and access in Türkiye. Note: the approved dose is 600 mg once daily (the 400 mg dose in some circulating texts is incorrect).
In some lung cancers, the ROS1 gene joins another gene (a fusion; for example, CD74-ROS1). This fusion creates a permanently activated receptor that continually signals the cell to "multiply" and becomes the cancer's engine.
Taletrectinib blocks the ROS1 fusion protein's ATP-binding site and interrupts signaling, silencing downstream growth pathways (MAPK/ERK, PI3K/AKT, STAT3). Two important advantages stand out: penetration into the brain (brain metastases are common in ROS1+ NSCLC) and retained activity against the G2032R mutation that confers resistance to previous treatments.
For whom? Only patients whose tumors have a detected ROS1 gene fusion and who have locally advanced or metastatic (advanced, not curable through surgery) non-small cell lung cancer. Without a ROS1 fusion, this drug has no role whatsoever — which makes molecular testing essential.
At which treatment line? FDA approval covers both situations : (1) First line — patients who have never received ROS1-targeted therapy (a TKI); and (2) Subsequent lines — patients previously treated with a ROS1 TKI (e.g., crizotinib, entrectinib) whose disease has progressed. It is therefore an option both as "initial treatment" and "when previous targeted therapy no longer works."
Two phase 2 studies evaluated taletrectinib in ROS1+ NSCLC, measuring its tumor shrinkage rate (objective response, ORR) and duration of response (DOR) . Results were presented separately for TKI-naïve and previously treated patients — an important distinction for showing the drug's value in both settings.
| Patient group | Objective response (ORR) | Duration of response (DOR) |
|---|---|---|
| TKI-naïve (TRUST-I) | 90% (95% CI 83–95) | Response ≥12 months in 72% |
| TKI-naïve (TRUST-II) | 85% (95% CI 73–93) | Response ≥12 months in 63% |
| Previously treated with a TKI (TRUST-I) | 52% (95% CI 39–64) | Response ≥6 months in 74% |
| Previously treated with a TKI (TRUST-II) | 62% (95% CI 46–75) | Response ≥6 months in 83% |
In summary: as initial treatment, it shrank tumors in the vast majority of patients (approximately 85–90%), and responses often lasted a long time. When a previous ROS1 drug was insufficient, a meaningful response was achieved in approximately one in two patients — an important gain for those with resistance. Because it penetrates the brain, activity has also been reported in patients with brain metastases .
Among drugs approved for ROS1+ NSCLC, taletrectinib is the newest. A brief overview:
| Drug | FDA approval | Key feature |
|---|---|---|
| Crizotinib (Xalkori) | 2016 (ROS1) | First ROS1 TKI; limited brain activity and activity against G2032R |
| Entrectinib (Rozlytrek) | 2019 | Good brain penetration; also approved for NTRK |
| Repotrectinib (Augtyro) | November 2023 | Next-generation; 1st line + later lines; active against G2032R |
| Taletrectinib (Ibtrozi) | 11 June 2025 | Next-generation; 1st line + later lines; active against G2032R; relatively fewer neurological adverse effects are emphasized |
Taletrectinib and repotrectinib are both "next-generation" drugs with similarly strong profiles; there is no direct head-to-head comparison. A highlighted claim for taletrectinib is that it causes relatively fewer neurological adverse effects (dizziness, etc.) than those prominent with some next-generation TKIs. Drug selection depends on disease characteristics, adverse effect profile, brain involvement, access, and physician experience.
- Liver toxicity: ALT/AST and bilirubin may rise; liver tests should be monitored regularly.
- Interstitial lung disease / pneumonitis (<5%): with a new/worsening cough, shortness of breath, or fever, the drug should be stopped immediately and the patient assessed.
- QTc prolongation (~12%): risk of serious arrhythmia; ECG and electrolyte (potassium, magnesium) monitoring; caution with other QT-prolonging drugs.
- Muscle pain + elevated CPK, hyperuricemia (gout attacks), rarely skeletal fractures.
- Embryo-fetal toxicity: harm during pregnancy; effective contraception for female and male patients during and after treatment; breastfeeding is not recommended.
- Photosensitivity: sun protection (for a period after the final dose as well).
| Common adverse effect | Frequency | Common adverse effect | Frequency |
|---|---|---|---|
| Nausea | ~44% | Headache | ~20% |
| Vomiting | ~31% | AST / ALT elevation | ~17–18% |
| Diarrhea | ~30% | Rash | ~17% |
| Fatigue | ~29% | Muscle pain | ~15% |
| Constipation | ~26% | Hyperuricemia | ~13% |
| Anemia (low red blood cell levels) | ~24% | QTc prolongation | ~12% |
| Loss of appetite | ~22% | Skeletal fracture | ~9% |
Overall, adverse effects predominantly involve the digestive system (nausea, vomiting, diarrhea), and most are manageable; serious effects (ILD, severe liver injury, arrhythmia) are uncommon but require close monitoring.
- CYP3A4 interactions: taletrectinib is broken down by CYP3A4 in the liver. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit) raise drug levels and increase toxicity. Strong inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) reduce efficacy. These should be avoided.
- Acid-reducing medications: because absorption depends on stomach acid, proton pump inhibitors (PPIs) and H2 blockers may reduce absorption; antacids should be taken at least 2 hours apart from taletrectinib administration.
- QT-prolonging drugs (certain antidepressants, antipsychotics, methadone, amiodarone, macrolides) increase arrhythmia risk when used together.
- Urate-lowering drugs: because the drug can raise uric acid, monitor uric acid alongside gout/urate treatments.
Administration: once daily, 600 mg, orally, on an empty stomach (no food for 2 hours before and 2 hours after taking it). Swallow capsules whole ; do not open, crush, or chew them. Taking the drug at the same time each day is recommended. Only the treating oncologist decides the dose and any adjustments; detailed dose adjustments are not provided in this monograph.
Pharmacokinetics: well absorbed; Tmax ~2–4 hours. Mainly excreted in feces (urine <10%). Elimination half-life ~30–40 hours — allowing once-daily dosing. Data indicate it can cross the blood-brain barrier.
- ROS1 G2032R (solvent-front) mutation: the most common resistance to ROS1 TKIs, particularly rendering crizotinib ineffective. Taletrectinib is among the few drugs that can largely retain activity against G2032R — increasing its value in resistant cases after previous treatment.
- Gatekeeper mutations (e.g., L2026M): these changes in the kinase region can impede drug binding; taletrectinib may retain activity against some.
- Bypass pathways: the tumor may escape by bypassing ROS1 and activating alternative pathways such as EGFR, MET, and KRAS/NRAS; ROS1 inhibition alone is then insufficient.
- EMT (epithelial–mesenchymal transition) and increased drug efflux pumps (e.g., ABCB1) have also been reported as mechanisms.
License: Taletrectinib (Ibtrozi) has not been licensed by the Turkish Ministry of Health.
Reimbursement: not covered by SGK reimbursement.
Consequence: the drug is not on the market in our country. When needed, it must be obtained from abroad and paid for by the patient.
- Molecular testing is essential. First, a ROS1 fusion must be laboratory-confirmed in the tumor; without it, the drug has no role.
- Off-Label Approval application. The patient's medical oncologistapplies to the Turkish Ministry of Health for approval for off-label drug use (documenting diagnosis, stage, ROS1 test result, and previous treatments).
- After approval, a prescription is issued.
- Import through the Turkish Pharmacists' Association (TEB). The drug is brought from abroad; the patient pays the cost. In some cases, seeking a court order may also be considered.
This process depends on regulations and may change over time. Consult the treating center's medication procurement unit for the current procedure.
Who is this drug for? Only patients with a detected ROS1 fusion and advanced non-small cell lung cancer. Without this mutation, the drug has no role — which makes prior molecular testing essential.
What can you expect? As initial treatment, it shrinks tumors in the vast majority of patients, with responses often lasting a long time; it also offers another chance if a previous ROS1 drug is insufficient. It is taken orally once daily.
What should you watch for? Take the drug on an empty stomach at the same time each day; ask your doctor about grapefruit and stomach medications (especially PPIs). New/worsening shortness of breath, cough, or fever should be reported to your oncology team without delay (a possible lung adverse effect). Watch for palpitations/fainting (heart rhythm), marked muscle pain, and a tendency to sunburn.
How is it obtained in Türkiye? Because it is not licensed here, access is possible only if your doctor obtains Off-Label Approval and the drug is brought from abroad; the patient bears the cost. The person who initiates this process is your treating medical oncologist — strictly avoid trying to obtain it online.
ROS1+ NSCLC is rare (~1–2%) but highly sensitive to targeted therapy; identifying the right patient (ROS1 testing) changes everything. Taletrectinib is the latest-generation TKIadded to this field, effective both as initial therapy and in patients resistant to a previous ROS1 drug — particularly with the G2032R mutation. Its brain penetration is also valuable in ROS1+ disease.
TRUST-I/II (phase 2): in TKI-naïve patients, ORR ~85–90% with durable responses (≥12 months in most); in pretreated patients, ORR ~52–62%. Activity against G2032R resistance and CNS activity are documented. FDA approval (11 June 2025) covers both 1st and subsequent lines. Approved dose: once daily 600 mg.
The basis is a phase 2single-arm response rate (not randomized survival superiority). There is no direct comparison with repotrectinib; it is unknown which next-generation TKI is superior. ILD, QT prolongation, liver toxicity, and embryo-fetal risks require close safety monitoring; CYP3A4 and acid-reducing drug interactions are important. The most decisive local limitation: it is neither licensed nor reimbursed in Türkiye.
In advanced NSCLC, comprehensive molecular testing (including ROS1) is essential. Taletrectinib may be considered for a ROS1+ patient either first line or after a previous ROS1 TKI; selection alongside alternatives such as repotrectinib accounts for adverse effects and access. In Türkiye, access requires Off-Label Approval + procurement from abroad with patient payment, so decisions often depend as much on accessibility as on efficacy.
Is there a genuine difference in efficacy/tolerability between taletrectinib and repotrectinib? How will its contribution to overall survival mature with randomized data? How do they compare in patients with brain metastases? What should follow resistance to taletrectinib? And for our country: when will licensing/reimbursement advance?
- The approved dose is 600 mg once daily (the 400 mg dose in some texts is incorrect); this document does not provide detailed dose adjustments.
- It applies only to confirmed ROS1 fusion-positive advanced NSCLC; other indications, including NTRK, are not FDA-approved.
- The indication includes both 1st line and treatment after a previous ROS1 TKI.
- The basis is phase 2 studies; data concern response rates, not randomized survival superiority.
- CYP3A4 and acid-reducing (PPI) interactions and QT/liver/lung monitoring are important.
- It is neither licensed nor reimbursed in Türkiye; FDA approval does not mean access.
- Only a medical oncologist who knows the patient decides whether to use it.
- FDA. Taletrectinib (Ibtrozi) approval — locally advanced/metastatic ROS1-positive NSCLC; 11 June 2025. Approved dose 600 mg/day; indication includes TKI-naïve and pretreated patients.
- TRUST-I (NCT04395677) and TRUST-II (NCT04919811) phase 2 studies — ORR: TKI-naïve 85–90%, pretreated 52–62%; duration of response and CNS activity.
- Product information / warnings: hepatotoxicity, interstitial lung disease/pneumonitis, QTc prolongation, hyperuricemia, myalgia/CPK, skeletal fractures, embryo-fetal toxicity; CYP3A4 and acid-reducing drug interactions.
- Other TKIs in ROS1+ NSCLC: crizotinib (2016), entrectinib (2019), repotrectinib (Augtyro, November 2023) — comparison context.
- Nuvation Bio / AnHeart Therapeutics and FDA approval/application announcements (2024–2025).
Editor's note: this monograph is for general information only; it is not medical advice, a diagnosis, or a treatment recommendation, and does not promote any product. Detailed drug dosing/dose adjustment information has deliberately not been included in this document; the approved daily dose is 600 mg, and administration is solely the treating physician's responsibility. Taletrectinib is a prescription oncology drug used only in patients with a confirmed ROS1 fusionand locally advanced/metastatic non-small cell lung cancer, under medical supervision; other uses, including NTRK, are not FDA-approved. The efficacy data presented come from phase 2 (TRUST-I/II) studies and concern response rates; randomized overall survival superiority has not been demonstrated. As a CYP3A4 substrate, it may interact with strong CYP3A4 inhibitors/inducers and grapefruit, as well as acid-reducing drugs; monitoring is required for QTc prolongation, interstitial lung disease, liver toxicity, and embryo-fetal risk. Taletrectinib has not been licensed by the Turkish Ministry of Health or included in SGK reimbursement in Türkiye; FDA approval does not mean a drug is licensed, accessible, or reimbursed in our country. Procurement from abroad depends on regulations and may change over time. Do not stop or change any medication without consulting your doctor; contact only your treating medical oncologist to obtain medication. Consult a doctor who knows you about every health decision.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.